Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Breast
Descriptor: Poor Prognosis


Reference Number: 6
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51, 172-8. (2001).
PubMed link      E-mail link

Reference Number: 8
Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
PubMed link      E-mail link

Reference Number: 9
Nagy, J. et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 5, 15-21. (1996).
PubMed link      E-mail link

Reference Number: 11
Yamashita, J. et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54, 1630-3 (1994).
PubMed link      E-mail link

Reference Number: 14
Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-65. (1999).
PubMed link      E-mail link

Reference Number: 16
Tsarfaty, I. et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 21, 397-408. (1999).
PubMed link      E-mail link

Reference Number: 232
Tolgay Ocal, I, Dolled-Filhart, M, D'Aquila, TG, Camp, RL, & Rimm, DL.  Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97:1841-8 (2003).
PubMed link      E-mail link

Reference Number: 331
Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res11, 2222-8 (2005)
PubMed link      E-mail link

Reference Number: 332
Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer  113, 678-82 (2005)
PubMed link      E-mail link

Reference Number: 360
Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14 715-7 (2005)
PubMed link      E-mail link

Reference Number: 526
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest. 87, 251-60 (2007)
PubMed link      E-mail link

Reference Number: 548
Chen HH, Su WC, Lin PW, Guo HR, Lee WY. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 103, 167-75 (2007)
PubMed link      E-mail link

Reference Number: 556
Garcia S, Dalès JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 38, 830-41 (2007)
PubMed link      E-mail link

Reference Number: 574
Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9, R8 (2007)
PubMed link      E-mail link

Reference Number: 576
Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 31, 49-58 (2007)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 685
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12909-14 (2009)
PubMed link      E-mail link

Reference Number: 716
Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12903-8 (2009)
PubMed link      E-mail link

Reference Number: 1177
Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 21, 66-81 (2012)
PubMed link      E-mail link

Reference Number: 1449
Inanc M1, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F, Elmali F. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 31, 801 (2014)
PubMed link      E-mail link

Reference Number: 1874
Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 10, 62 (2015)
PubMed link      E-mail link